The results revealed that PA-CM significantly decreased the levels of phosphorylated JAK2 (Y1007/Y1008) and phosphorylated STAT3 (tyr705) proteins in three human CCA cells in a dose-dependent manner (Figure 5A–C and Figure S3). The gene discussed is JAK2; the disease is cholangiocarcinoma.